4/A: Vaccinex COO Elizabeth Evans Corrects Stock Option Transaction Details in Amended SEC Filing

Elizabeth Evans, COO of Vaccinex, files an amended SEC Form 4/A to correct the transaction date and exercise price of a stock option grant.

Summary

• Elizabeth Evans, Chief Operating Officer of Vaccinex, Inc. [VCNX], filed an amendment to a Form 4 (Form 4/A) with the Securities and Exchange Commission.
• The amendment corrects an administrative error in the original filing, specifically regarding the transaction date and exercise price of a stock option.
• The correct transaction date for the stock option grant is March 21, 2024, not March 20, 2024 as previously stated.
• The correct exercise price is $8.21 per share, instead of the $8.32 listed in the original Form 4.
• The stock option grant of 1,341 shares was made under the company's 2018 Omnibus Incentive Plan and vests one-fourth on each of the first four anniversaries of the grant date.

Sentiment

Score: 7

Explanation: The document is a routine regulatory filing correcting a minor error. It doesn't indicate any significant positive or negative developments for the company, but transparency is generally viewed favorably.

Industry Context

This filing is a routine disclosure related to executive compensation and stock ownership, common in publicly traded companies. It provides transparency to investors regarding the holdings and transactions of company insiders.

Stakeholder Impact

• The correction provides accurate information to shareholders regarding executive compensation.

Key Dates

Keywords

SEC Filing, Form 4/A, Vaccinex, Stock Option, Elizabeth Evans, VCNX, Amendment